Exelixis's oncology ambitions on track with European Cometriq approval
This article was originally published in Scrip
The European Commission has approved Exelixis's Cometriq (cabozantinib) for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma (MTC). The product is licensed to Swedish Orphan Biovitrum (Sobi) in Europe. The decision follows a positive recommendation from the EMA's CHMP in December (scripintelligence.com, 20 December 2014).